Achillion Pharmaceuticals has announced the addition of two members to the senior management team, including the appointment of a new general counsel and secretary, and a new senior vice president of regulatory affairs.
Martha Manning joined Achillion in February as general counsel. Previously, she held the same role from 2013 to 2016 at iCeutica, a drug development company. Prior to that, she served as chief legal officer of OraPharma, a J&J spinout company, from 2011 to 2012, when the company was acquired by Valeant. She joined OraPharma from Sandoz, the generic pharmaceutical division of Novartis, where she served as general counsel from 2008 to 2011.
Amy Jennings joined Achillion in January and serves as SVP of Regulatory Affairs. She was previously with Sanofi, where she was the head of U.S. regulatory for diabetes. Prior to Sanofi, Jennings assumed roles of increasing responsibility at Bristol-Myers Squibb within Regulatory over more than 12 years, culminating in her leading U.S. regulatory for CV/Metabolics.